CoChat
Sign Up
Cited by 260Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Open access
Theunis, Clara, Crespo-Biel, Natalia, Gafner, Valérie, Pihlgren, Maria, López-Deber, María Pilar, Reis, Pedro, Hickman, David T., Adolfsson, Oskar, Chuard, Nathalie, Ndao, Dorin Mlaki, Borghgraef, Peter, Devijver, Herman, Van Leuven, Fred, Pfeifer, Andrea, Muhs, Andreas·2013·PLoS ONE
DOI 10.1371/journal.pone.0072301PMC PMC3747157
Open this paper in CoChat — free accountOpen PDF

Abstract

Progressive aggregation of protein Tau into oligomers and fibrils correlates with cognitive decline and synaptic dysfunction, leading to neurodegeneration in vulnerable brain regions in Alzheimer's disease. The unmet need of effective therapy for Alzheimer's disease, combined with problematic pharmacological approaches, led the field to explore immunotherapy, first against amyloid peptides and recently against protein Tau. Here we adapted the liposome-based amyloid vaccine that proved safe and efficacious, and incorporated a synthetic phosphorylated peptide to mimic the important phospho-epitope of protein Tau at residues pS396/pS404. We demonstrate that the liposome-based vaccine elicited, rapidly and robustly, specific antisera in wild-type mice and in Tau.P301L mice. Long-term vaccination proved to be safe, because it improved the clinical condition and reduced indices of tauopathy in the brain of the Tau.P301L mice, while no signs of neuro-inflammation or other adverse neurological effects were observed. The data corroborate the hypothesis that liposomes carrying phosphorylated peptides of protein Tau have considerable potential as safe and effective treatment against tauopathies, including Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0072301

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CD spectrum of ACI-35 corresponds to β-sheet secondary structure. The CD spectrum of ACI-35 at (1∶9) dilution in PBS. The spectrum of liposomes lacking the phospho-peptide was subtracted to the signal of ACI-35 for baseline correction. The spectrum shows a maximum around 199.5 nm and a broad minimum around 218 nm.
Figure 1 CD spectrum of ACI-35 corresponds to β-sheet secondary structure. The CD spectrum of ACI-35 at (1∶9) dilution in PBS. The spectrum of liposomes lacking the phospho-peptide was subtracted to the signal of ACI-35 for baseline correction. The spectrum shows a maximum around 199.5 nm and a broad minimum around 218 nm.CC BY · PubMed Central
Figure 2 ACI-35 elicits robust and specific antisera against Tau in wild-type and Tau.P301L mice. (A) Vaccination schedule with ACI-35 in wild-type mice is shown schematically with s.c. injections represented by the syringes and the bleedings by the letter B with a number. Antisera titers were measured by ELISA on the phosphorylated antigenic sequence incorporated in the vaccine (pTau peptide), and on the non-phosphorylated peptide of the same primary amino acid sequence (Tau peptide) (see text for details). Data are presented as mean± SD. Statistical analysis: one-way ANOVA followed by Bonferroni multiple comparison test (**p<0.01, **** p<0.0001) and by unpaired student's t-test (**** p<0.0001). (B) Similar vaccination with ACI-35 of Tau.P301L mice and analysis by ELISA. Data are presented as mean± SD. Statistical analysis by unpaired student's t-test (** p<0.01; **** p<0.0001) (C) TAUPIR with antisera from ACI-35 vaccinated wild-type mice and Tau.P301L mice demonstrated a specific reaction with neurofibrillary tangles and neuropil threads in forebrain of biGT mice. IHC with Mab AT100 is included for comparison. IHC with sera from Tau.P301L mice injected with PBS or from Tau.P301L mice that were not vaccinated, were devoid of specific antibodies and auto-antibodies against human protein Tau. Scale bars: 50 µm.
Figure 2 ACI-35 elicits robust and specific antisera against Tau in wild-type and Tau.P301L mice. (A) Vaccination schedule with ACI-35 in wild-type mice is shown schematically with s.c. injections represented by the syringes and the bleedings by the letter B with a number. Antisera titers were measured by ELISA on the phosphorylated antigenic sequence incorporated in the vaccine (pTau peptide), and on the non-phosphorylated peptide of the same primary amino acid sequence (Tau peptide) (see text for details). Data are presented as mean± SD. Statistical analysis: one-way ANOVA followed by Bonferroni multiple comparison test (**p<0.01, **** p<0.0001) and by unpaired student's t-test (**** p<0.0001). (B) Similar vaccination with ACI-35 of Tau.P301L mice and analysis by ELISA. Data are presented as mean± SD. Statistical analysis by unpaired student's t-test (** p<0.01; **** p<0.0001) (C) TAUPIR with antisera from ACI-35 vaccinated wild-type mice and Tau.P301L mice demonstrated a specific reaction with neurofibrillary tangles and neuropil threads in forebrain of biGT mice. IHC with Mab AT100 is included for comparison. IHC with sera from Tau.P301L mice injected with PBS or from Tau.P301L mice that were not vaccinated, were devoid of specific antibodies and auto-antibodies against human protein Tau. Scale bars: 50 µm.CC BY · PubMed Central
Figure 3 Biochemical analysis of brain from Tau.P301L mice vaccinated with ACI-35. (A) Fractionation scheme of total brain homogenates from Tau.P301L mice to generate soluble (S1) and sarcosyl insoluble fractions (SInT). (B) Representative western blots of S1 and SInT fractions from forebrain and from brainstem of two untreated terminal Tau.P301L mice (age 10 months) developed for total protein Tau (Mab Tau5), for total human protein Tau (Mab HT7) and for phosphorylated Tau (antibodies pT231, pS396 and pS404 as indicated). (C) Reduction of pS396 in soluble fraction of brainstem and forebrain (p = 0.026 and 0.0523, respectively, Student's t-test) from ACI-35 vaccinated Tau.P301L mice, relative to PBS injected mice. (D) Reduction of pS396 (p = 0.0091, Mann Whitney test) and HT7 (p = 0.0706, Mann Whitney test) in SInT in forebrain by ACI-35 vaccination of Tau.P301L mice. (E) Reduction of tangled neurons, marked by IHC for AT100 or pS422, in the forebrain of ACI-35 vaccinated Tau.P301L mice after 3 months of treatment. Data: mean± SEM.
Figure 3 Biochemical analysis of brain from Tau.P301L mice vaccinated with ACI-35. (A) Fractionation scheme of total brain homogenates from Tau.P301L mice to generate soluble (S1) and sarcosyl insoluble fractions (SInT). (B) Representative western blots of S1 and SInT fractions from forebrain and from brainstem of two untreated terminal Tau.P301L mice (age 10 months) developed for total protein Tau (Mab Tau5), for total human protein Tau (Mab HT7) and for phosphorylated Tau (antibodies pT231, pS396 and pS404 as indicated). (C) Reduction of pS396 in soluble fraction of brainstem and forebrain (p = 0.026 and 0.0523, respectively, Student's t-test) from ACI-35 vaccinated Tau.P301L mice, relative to PBS injected mice. (D) Reduction of pS396 (p = 0.0091, Mann Whitney test) and HT7 (p = 0.0706, Mann Whitney test) in SInT in forebrain by ACI-35 vaccination of Tau.P301L mice. (E) Reduction of tangled neurons, marked by IHC for AT100 or pS422, in the forebrain of ACI-35 vaccinated Tau.P301L mice after 3 months of treatment. Data: mean± SEM.CC BY · PubMed Central
Figure 4 Improved clinical parameters of Tau.P301L mice vaccinated with ACI-35. (A) The left panel shows the evolution of the bodyweight of Tau.P301L mice over 3 months of ACI-35 vaccination relative to PBS injected Tau.P301L mice. The panel on the right presents the loss in bodyweight of the Tau.P301L mice at day 91 relative to the start of the study (day -7). Data: mean± SEM (p = 0.094, unpaired Student's t-test). (B) Clasping score of vaccinated Tau.P301L mice compared to placebo injected Tau.P301L mice. (C) Rotarod performance of ACI-35 vaccinated Tau.P301L mice compared to PBS-injected Tau.P301L mice, tested over 300 sec on the accelerating rod (see Methods section for details). Data: mean± SEM. (E) Mortality of Tau.P301L mice vaccinated with ACI-35 versus placebo Tau.P301L mice.
Figure 4 Improved clinical parameters of Tau.P301L mice vaccinated with ACI-35. (A) The left panel shows the evolution of the bodyweight of Tau.P301L mice over 3 months of ACI-35 vaccination relative to PBS injected Tau.P301L mice. The panel on the right presents the loss in bodyweight of the Tau.P301L mice at day 91 relative to the start of the study (day -7). Data: mean± SEM (p = 0.094, unpaired Student's t-test). (B) Clasping score of vaccinated Tau.P301L mice compared to placebo injected Tau.P301L mice. (C) Rotarod performance of ACI-35 vaccinated Tau.P301L mice compared to PBS-injected Tau.P301L mice, tested over 300 sec on the accelerating rod (see Methods section for details). Data: mean± SEM. (E) Mortality of Tau.P301L mice vaccinated with ACI-35 versus placebo Tau.P301L mice.CC BY · PubMed Central
Figure 5 No increased inflammatory response in ACI-35 treated Tau.P301L mice. (A) IHC did not reveal marked differences in inflammation-related parameters in forebrain of ACI-35 vaccinated Tau.P301L mice, relative to PBS-injected Tau.P301L mice. IHC reaction with the different specific antibodies, specified in the captions, was analyzed by image analysis (details see Methods section) and presented as mean± SEM. Scale bars: 50 µm. (B) Western blotting for GFAP of total brain homogenates from Tau.P301L mice vaccinated with ACI-35 (n = 34) or injected with PBS (n = 33). Data presented as mean± SEM. (C) ELISPOT analysis of IFN-γ and IL-4 production by T cells isolated from spleens of naive mice or from mice immunized by either ACI-35 or with recombinant protein Tau. Splenocytes were re-stimulated with medium (cells alone), recombinant Tau protein (100 µg/ml) or with the phosphorylated peptide used in the ACI-35 vaccine and with its un-phosphorylated counterpart (1 µg/ml). Results are expressed as the number of foci (spots per million cells) +SD (n = 10 mice). Statistical analysis: two-way ANOVA followed by Bonferroni multiple comparison test (*** p<0.001).
Figure 5 No increased inflammatory response in ACI-35 treated Tau.P301L mice. (A) IHC did not reveal marked differences in inflammation-related parameters in forebrain of ACI-35 vaccinated Tau.P301L mice, relative to PBS-injected Tau.P301L mice. IHC reaction with the different specific antibodies, specified in the captions, was analyzed by image analysis (details see Methods section) and presented as mean± SEM. Scale bars: 50 µm. (B) Western blotting for GFAP of total brain homogenates from Tau.P301L mice vaccinated with ACI-35 (n = 34) or injected with PBS (n = 33). Data presented as mean± SEM. (C) ELISPOT analysis of IFN-γ and IL-4 production by T cells isolated from spleens of naive mice or from mice immunized by either ACI-35 or with recombinant protein Tau. Splenocytes were re-stimulated with medium (cells alone), recombinant Tau protein (100 µg/ml) or with the phosphorylated peptide used in the ACI-35 vaccine and with its un-phosphorylated counterpart (1 µg/ml). Results are expressed as the number of foci (spots per million cells) +SD (n = 10 mice). Statistical analysis: two-way ANOVA followed by Bonferroni multiple comparison test (*** p<0.001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 78 references

Cited by

Sorted by citations

See all 260

Related

Metadata

Authors
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., Borghgraef, P., Devijver, H., Van Leuven, F., Pfeifer, A., & Muhs, A.
Affiliations
  • KU Leuven (BE)
  • AC Immune (Switzerland) (CH)
ORCID
Venue
PLoS ONE
Publisher
Public Library of Science (PLoS)
Published
2013-08-19
Volume
8
Issue
8
Pages
e72301
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0072301
PMC
PMC3747157
OpenAlex
W2090968981
Cited by
259
References
78
Citations by year
2026: 9 · 2025: 16 · 2024: 25 · 2023: 17 · 2022: 22 · 2021: 23 · 2020: 25 · 2019: 23 · 2018: 27 · 2017: 22 · 2016: 19 · 2015: 13 · 2014: 16 · 2013: 1
FWCI
11.37
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
tau protein, tau immunotherapy, tauopathy, Alzheimer's disease, vaccine safety, neuroinflammation, tau aggregation
MeSH terms
Animals, Brain, Disease Models, Animal, Humans, Liposomes, Mice, Transgenic, Peptides, Phosphoproteins, Phosphorylation, Psychomotor Performance, Vaccination, tau Proteins, Treatment Outcome, Alzheimer Vaccines, Tauopathies, Mice, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review